Company intelligence / Profile preview
Plakous Therapeutics
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Received rare pediatric disease and orphan drug designations from FDA for NEC prevention. Preclinical studies show significant decreases in NEC disease severity and number of gut segments affected. For osteoarthritis, preclinical models demonstrate significant protection of joint cartilage.
- Therapeutic areas
- GastroenterologyRheumatology
- Modalities
- BiotherapeuticsHuman Placental Extract (HPE)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Mayo Clinic
Beyond the preview
Go deeper on Plakous Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Plakous Therapeutics.